<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096326</url>
  </required_header>
  <id_info>
    <org_study_id>2034-201-008</org_study_id>
    <nct_id>NCT04096326</nct_id>
  </id_info>
  <brief_title>AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines</brief_title>
  <official_title>A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range&#xD;
      of doses for the treatment of moderate to severe glabellar lines (GL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Actual">September 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: To compare the efficacy between placebo and a range of doses of AGN-151586 for the treatment of GL (Glabellar Lines) in participants with moderate to severe GL</measure>
    <time_frame>Baseline Day 1 to Day 7</time_frame>
    <description>Achievement of a ≥ 2-grade improvement from baseline on the FWS (Facial Wrinkle Scale With Photonumeric Guide) according to investigator assessments of GL severity at maximum frown at any postintervention timepoint through Day 7.&#xD;
The investigator evaluates the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: To compare the safety between placebo and a range of doses of AGN-151586 for the treatment of GL in participants with moderate to severe GL</measure>
    <time_frame>Baseline Day 1 to Day 42</time_frame>
    <description>To assess the safety of treatment with AGN-151586 in participants based on the number of participants who experience one or more Treatment Emergent Adverse Events (TEAE).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Glabellar Lines</condition>
  <arm_group>
    <arm_group_label>AGN-151586</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-151586</intervention_name>
    <description>Participants will receive 5 injections (1 in the procerus, 2 in each of the bilateral corrugators). Up to 5 cohorts will be enrolled in this study.</description>
    <arm_group_label>AGN-151586</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive 5 injections (1 in the procerus, 2 in each of the bilateral corrugators) of placebo matched AGN-151586</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Female participants willing to minimize the risk of inducing pregnancy for the duration of&#xD;
        the clinical study and follow-up period (at least 10 weeks after study intervention).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known immunization or hypersensitivity to any botulinum neurotoxin serotype&#xD;
&#xD;
          -  Any medical condition that may put the participant at increased risk with exposure to&#xD;
             AGN-151586, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic&#xD;
             lateral sclerosis, or any other condition that might interfere with neuromuscular&#xD;
             function&#xD;
&#xD;
          -  Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick&#xD;
             sebaceous skin, or the inability to substantially lessen facial lines even by&#xD;
             physically spreading them apart, as determined by the investigator&#xD;
&#xD;
          -  Any brow or eyelid ptosis, as determined by the investigator&#xD;
&#xD;
          -  Infection or skin disorder at the injection sites&#xD;
&#xD;
          -  History of facial nerve palsy&#xD;
&#xD;
          -  Any uncontrolled systemic disease&#xD;
&#xD;
          -  Anticipated need for treatment with botulinum neurotoxin of any serotype for any&#xD;
             reason during the study (other than study intervention)&#xD;
&#xD;
          -  Anticipated need for surgery or overnight hospitalization during the study&#xD;
&#xD;
          -  Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow&#xD;
             lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery)&#xD;
&#xD;
          -  Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg,&#xD;
             Gore-Tex®), and/or autologous fat transplantation&#xD;
&#xD;
          -  Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 30 days of Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ava T. Shamban MD, INC</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baumann Cosmetic and Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WDC Cosmetic and Research, PLLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGL LLC</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates; The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <disposition_first_submitted>July 12, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>July 12, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 16, 2021</disposition_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

